Ribonucleotide reductase M2B inhibits cell migration and spreading by early growth response protein 1-mediated phosphatase and tensin homolog/Akt1 pathway in hepatocellular carcinoma

Hepatology

Volumn 59, Issue 4, 2014, Pages 1459-1470

  Tian, Hua ^a   Ge, Chao ^a   Li, Hong ^a   Zhao, Fangyu ^a   Hou, Helei ^a   Chen, Taoyang ^b   Jiang, Guoping ^c   Xie, Haiyang ^c   Cui, Ying ^d   Yao, Ming ^a   Li, Jinjun ^a  

^a School of Medicine   (China)

^b Qi Dong Liver Cancer Institute   (China)

^c ZHEJIANG UNIVERSITY   (China)

^d Guangxi Cancer Institute   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EARLY GROWTH RESPONSE FACTOR 1; NERVE CELL ADHESION MOLECULE; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; RIBONUCLEOTIDE REDUCTASE; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR SLUG; UVOMORULIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PROGNOSIS; CARCINOMA CELL; CELL MIGRATION; CELL SPREADING; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEEDBACK SYSTEM; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; MALE; METASTASIS INHIBITION; MIDDLE AGED; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR INVASION; UPREGULATION;

CADHERINS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE PROGRESSION; DOWN-REGULATION; EARLY GROWTH RESPONSE PROTEIN 1; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RIBONUCLEOTIDE REDUCTASES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84896494354     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26929     Document Type: Article

References (39)

1. Wang X, Zhang A, Sun H. Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma. Hepatology 2013;57:2072-2077.
2. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011;331:1559-1564.
3. Mitsunobu M, Toyosaka A, Oriyama T, Okamoto E, Nakao N. Intrahepatic metastases in hepatocellular carcinoma: the role of the portal vein as an efferent vessel. Clin Exp Metastasis 1996;14:520-529.
4. Lindsay CK, Sinha CC, Thorgeirsson UP. Morphological study of vascular dissemination in a metastatic hepatocellular carcinoma model in the monkey. Hepatology 1997;26:1209-1215.
5. De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 2013;13:97-110.
6. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 2006;66:8319-8326.
7. Zhou B, Liu X, Mo X, Xue L, Darwish D, Qiu W, et al. The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53. Cancer Res 2003;63:6583-6594.
8. Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, et al. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 2000;404:42-49.
9. Morikawa T, Hino R, Uozaki H, Maeda D, Ushiku T, Shinozaki A, et al. Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro. Hum Pathol 2010;41:1742-1748.
10. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 2004;23:1539-1548.
11. Hsu NY, Wu JY, Liu X, Yen Y, Chen CY, Chou MC, et al. Expression status of ribonucleotide reductase small subunits hRRM2/p53R2 as prognostic biomarkers in stage I and II non-small cell lung cancer. Anticancer Res 2011;31:3475-3481.
12. Liu X, Lai L, Wang X, Xue L, Leora S, Wu J, et al. Ribonucleotide reductase small subunit M2B prognoses better survival in colorectal cancer. Cancer Res 2011;71:3202-3213.
13. Okumura H, Natsugoe S, Yokomakura N, Kita Y, Matsumoto M, Uchikado Y, et al. Expression of p53R2 is related to prognosis in patients with esophageal squamous cell carcinoma. Clin Cancer Res 2006;12:3740-3745.
14. Piao C, Youn CK, Jin M, Yoon SP, Chang IY, Lee JH, et al. MEK2 regulates ribonucleotide reductase activity through functional interaction with ribonucleotide reductase small subunit p53R2. Cell Cycle 2012;11:3237-3249.
15. Piao C, Jin M, Kim HB, Lee SM, Amatya PN, Hyun JW, et al. Ribonucleotide reductase small subunit p53R2 suppresses MEK-ERK activity by binding to ERK kinase 2. Oncogene 2009;28:2173-2184.
16. Li H, Ge C, Zhao F, Yan M, Hu C, Jia D, et al. Hypoxia-inducible factor 1 alpha-activated angiopoietin-like protein 4 contributes to tumor metastasis via vascular cell adhesion molecule-1/integrin beta1 signaling in human hepatocellular carcinoma. Hepatology 2011;54:910-919.
17. Luo W, Liu J, Li J, Zhang D, Liu M, Addo JK, et al. Anti-cancer effects of JKA97 are associated with its induction of cell apoptosis via a Bax-dependent and p53-independent pathway. J Biol Chem 2008;283:8624-8633.
18. Xue XB, Xiao CW, Zhang H, Lu AG, Gao W, Zhou ZQ, et al. Oncolytic adenovirus SG600-IL24 selectively kills hepatocellular carcinoma cell lines. World J Gastroenterol 2010;16:4677-4684.
19. Calvisi DF, Donninger H, Vos MD, Birrer MJ, Gordon L, Leaner V, et al. NORE1A tumor suppressor candidate modulates p21CIP1 via p53. Cancer Res 2009;69:4629-4637.
20. Zhang K, Wu J, Wu X, Wang X, Wang Y, Zhou N, et al. p53R2 inhibits the proliferation of human cancer cells in association with cell-cycle arrest. Mol Cancer Ther 2011;10:269-278.
21. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-890.
22. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene 2005;24:7443-7454.
23. Virolle T, Adamson ED, Baron V, Birle D, Mercola D, Mustelin T, et al. The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling. Nat Cell Biol 2001;3:1124-1128.
24. Osada T, Sakamoto M, Ino Y, Iwamatsu A, Matsuno Y, Muto T, et al. E-cadherin is involved in the intrahepatic metastasis of hepatocellular carcinoma. Hepatology 1996;24:1460-1467.
25. Sugimachi K, Tanaka S, Kameyama T, Taguchi K, Aishima S, Shimada M, et al. Transcriptional repressor snail and progression of human hepatocellular carcinoma. Clin Cancer Res 2003;9:2657-2664.
26. Huang J, Deng Q, Wang Q, Li KY, Dai JH, Li N, et al. Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet 2012;44:1117-1121.
27. Muller PA, Vousden KH, Norman JC. p53 and its mutants in tumor cell migration and invasion. J Cell Biol 2011;192:209-218.
28. Byun DS, Chae KS, Ryu BK, Lee MG, Chi SG. Expression and mutation analyses of P53R2, a newly identified p53 target for DNA repair in human gastric carcinoma. Int J Cancer 2002;98:718-723.
29. Tamura M, Gu J, Takino T, Yamada KM. Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas. Cancer Res 1999;59:442-449.
30. Sze KM, Wong KL, Chu GK, Lee JM, Yau TO, Ng IO. Loss of phosphatase and tensin homolog enhances cell invasion and migration through AKT/Sp-1 transcription factor/matrix metalloproteinase 2 activation in hepatocellular carcinoma and has clinicopathologic significance. Hepatology 2011;53:1558-1569.
31. Casas E, Kim J, Bendesky A, Ohno-Machado L, Wolfe CJ, Yang J. Snail2 is an essential mediator of Twist1-induced epithelial mesenchymal transition and metastasis. Cancer Res 2011;71:245-254.
32. Hajra KM, Chen DY, Fearon ER. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res 2002;62:1613-1618.
33. Sun D, Sun B, Liu T, Zhao X, Che N, Gu Q, et al. Slug promoted vasculogenic mimicry in hepatocellular carcinoma. J Cell Mol Med 2013;17:1038-1047.
34. Qiao M, Sheng S, Pardee AB. Metastasis and AKT activation. Cell Cycle 2008;7:2991-2996.
35. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008;14:818-829.
36. Fenouille N, Tichet M, Dufies M, Pottier A, Mogha A, Soo JK, et al. The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion. PLoS One 2012;7:e40378.
37. Kimura T, Takeda S, Sagiya Y, Gotoh M, Nakamura Y, Arakawa H. Impaired function of p53R2 in Rrm2b-null mice causes severe renal failure through attenuation of dNTP pools. Nat Genet 2003;34:440-445.
38. Xu N, Hegarat N, Black EJ, Scott MT, Hochegger H, Gillespie DA. Akt/PKB suppresses DNA damage processing and checkpoint activation in late G2. J Cell Biol 2010;190:297-305.
39. Wanzel M, Kleine-Kohlbrecher D, Herold S, Hock A, Berns K, Park J, et al. Akt and 14-3-3eta regulate Miz1 to control cell-cycle arrest after DNA damage. Nat Cell Biol 2005;7:30-41.